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Abstract
Purpose Nuclear cardiology is widely used to diagnose coro-
nary artery disease and to guide patient management, but data
on current practices, radiation dose-related best practices, and
radiation doses are scarce. To address these issues, the IAEA
conducted a worldwide study of nuclear cardiology practice.
We present the European subanalysis.
Methods InMarch 2013, the IAEA invited laboratories across
the world to document all SPECT and PET studies performed
in one week. The data included age, gender, weight, radio-
pharmaceuticals, injected activities, camera type, positioning,
hardware and software. Radiation effective dose was calculat-
ed for each patient. A quality score was defined for each lab-
oratory as the number followed of eight predefined best prac-
tices with a bearing on radiation exposure (range of quality
score 0 – 8). The participating European countries were
assigned to regions (North, East, South, and West). Compar-
isons were performed between the four European regions and
between Europe and the rest-of-the-world (RoW).
Results Data on 2,381 European patients undergoing nuclear
cardiology procedures in 102 laboratories in 27 countries were
collected. A cardiac SPECTstudy was performed in 97.9% of
* Oliver Lindner
olindner@hdz-nrw.de
1 Institute of Radiology, Nuclear Medicine and Molecular Imaging,
Heart and Diabetes Center North Rhine-Westphalia Bochum,
University Hospital of the Ruhr University, Georgstr. 11, 32545 Bad
Oeynhausen, Germany
2 Section of Nuclear Medicine and Diagnostic Imaging, Division of
Human Health, International Atomic Energy Agency,
Vienna, Austria
3 Division of Cardiology, Department of Medicine, Columbia
University Medical Center and New York-Presbyterian Hospital,
New York, NY, USA
4 Institute of Biostructures and Bioimaging, National Council of
Research, Naples, Italy
5 Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau,
Universitat Autónoma de Barcelona, Barcelona, Spain
6 Department of Nuclear Medicine and Cardiac Imaging, University
Hospital Zurich, Zurich, Switzerland
7 Department of Cardiology, Sismanoglio Hospital, Athens, Greece
8 Turku PET Centre, University of Turku, and Turku University
Hospital, Turku, Finland
9 National Heart and Lung Institute, Imperial College London,
London, UK
10 Department of Nuclear Medicine, Royal Brompton and Harefield
Hospitals, London, UK
11 Quanta Diagnóstico & Terapia, Curitiba, Brazil
12 Department of Cardiology, Houston Methodist DeBakey Heart and
Vascular Center, Houston, TX, USA
13 Department of Cardiology, All India Institute of Medical Sciences,
New Delhi, India
14 Department of Nuclear Medicine, Royal Melbourne Hospital and
University of Melbourne, Melbourne, Australia
15 Radiation Protection of Patients Unit, International Atomic Energy
Agency, Vienna, Austria
16 Department of Radiology, Massachusetts General Hospital and
Harvard Medical School, Boston, MA, USA
17 Department of Radiology, Columbia University Medical Center and
New York-Presbyterian Hospital, New York, NY, USA
Eur J Nucl Med Mol Imaging (2016) 43:718–728
DOI 10.1007/s00259-015-3270-8
the patients, and a PET study in 2.1 %. The average effective
dose of SPECT was 8.0 ± 3.4 mSv (RoW 11.4 ± 4.3 mSv;
P < 0.001) and of PET was 2.6 ± 1.5 mSv (RoW 3.8 ±
2.5 mSv; P<0.001). The mean effective doses of SPECT
and PET differed between European regions (P<0.001 and
P=0.002, respectively). The mean quality score was 6.2±
1.2, which was higher than the RoW score (5.0 ± 1.1;
P<0.001). Adherence to best practices did not differ signifi-
cantly among the European regions (range 6 to 6.4; P=0.73).
Of the best practices, stress-only imaging and weight-adjusted
dosing were the least commonly used.
Conclusion In Europe, the mean effective dose from nuclear
cardiology is lower and the average quality score is higher
than in the RoW. There is regional variation in effective dose
in relation to the best practice quality score. A possible reason
for the differences between Europe and the RoW could be the
safety culture fostered by actions under the Euratom directives
and the implementation of diagnostic reference levels. Stress-
only imaging and weight-adjusted activity might be targets for
optimization of European nuclear cardiology practice.
Keywords Nuclear cardiology .Myocardial perfusion
scintigraphy . SPECT . PET . Radiation dose . Best practices .
Quality of care . Europe
Introduction
Nuclear cardiology is widely used to image myocardial per-
fusion and viability as well as left ventricular function nonin-
vasively using SPECT or PET. The classical imaging proce-
dure to diagnose coronary artery disease consists of stress
imaging after radiopharmaceutical injection during dynamic
exercise or pharmacological stress with adenosine,
dipyridamole, regadenoson or dobutamine, and rest imaging.
The radiopharmaceuticals used for SPECTare most common-
ly the 99mTc-labelled compounds sestamibi or tetrofosmin and
less commonly 201Tl-labelled compounds. The PET radio-
pharmaceuticals 13N-ammonia, 82Rb and 15O-water are used
for PET perfusion imaging, and 18F FDG for viability
imaging.
The information provided by nuclear cardiology can effec-
tively diagnose coronary artery disease [1], stratify risk [2, 3],
and guide patient management [4, 5], but it also exposes pa-
tients to the assumed risks of radiation exposure [6–8]. As
imaging can be performed with several protocols, radiophar-
maceuticals and additional techniques (e.g. attenuation correc-
tion), a variety of strategies and best practice procedures exist
to obtain diagnostic quality images while minimizing expo-
sure of the individual patient to radiation [9–11].
Information on current nuclear cardiology practice and ra-
diation doses is scarce and mostly confined to single countries
[11–13]. A worldwide study was therefore conducted during
March and April 2013 to evaluate nuclear cardiology practice,
and identify practices related to radiation dose and hence po-
tential areas for improvement [14]. We present here the Euro-
pean data from the survey and a comparison with data from
the rest-of-the-world (RoW).
Materials and methods
Study design and survey
This study used data collected as part of an IAEA cross-
sectional study of nuclear cardiology laboratories around the
world. Participating laboratories provided information about
their nuclear cardiology practice from consecutive patients
over one week between 18 March and 22 April 2013. Radio-
pharmaceuticals and administered activities in each laboratory
were selected based on standard practice in that laboratory.
During this period there was no 99mTc generator shortage that
may have impacted standard laboratory practice. A detailed
description of the study design and data collection is published
elsewhere [14].
A local investigator at each site provided data on laboratory
and patient demographics and clinical characteristics for each
patient undergoing a SPECT or PET nuclear cardiology pro-
cedure completed during the week. Procedures using planar
techniques, e.g. multigated acquisition scans, were not includ-
ed. The collected data included patient age, gender, weight,
radiopharmaceuticals, injected activities, camera type, patient
positioning, attenuation correction and image processing. Da-
ta omissions and errors were clarified individually with the
laboratories.
The Columbia University Institutional Review Board ap-
proved the study, and deemed it exempt from the requirements
of US federal regulations for the protection of human subjects
(45 CFR 46) because no individually identifiable health infor-
mation was collected.
Radiation dose estimation
The primary outcome measure was patient effective dose,
which was calculated from the radiopharmaceutical(s) admin-
istered and their activities, using the methodology outlined by
the International Commission on Radiological Protection
(ICRP), with the administered activity of each isotope multi-
plied by a conversion coefficient found in ICRP Publication
120 [15]. The only exception was 82Rb, for which the dose
conversion coefficient of Senthamizhchelvan et al. [16],
which is derived frommore human data, was used to calculate
the effective dose. We also evaluated the achievement in each
laboratory of a median effective dose of ≤9 mSv, a target
established in recommendations of the American Society of
Nuclear Cardiology [17]. Radiation doses from imaging with
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attenuation correction, when performed, were not collected,
since attenuation correction is generally associated with doses
far less than those used in SPECT or PET imaging [18].
Best practice quality score
Eight laboratory-level best practices pertaining to radiation
dose according to current guidelines were determined a priori
by an expert panel (Table 1) [10, 19, 20]. Each laboratory’s
adherence to each practice was determined and a quality score
for each laboratory was defined as the number of best prac-
tices out of the total of eight adhered to by that laboratory. A
quality score of ≥6 was prespecified as a desirable level.
Statistical methods
Mean (± standard deviation) and medians (interquartile range,
IQR) were used to describe continuous variables, and were
compared using analysis of variance and the Kruskal-Wallis
test, respectively. The chi-squared test was used to compare
categorical variables. The participating European countries
were assigned to regions (North, East, South and West) ac-
cording to the UN geoscheme (Table 2). Comparisons were
performed among the four regions and between Europe and
the RoW.
The association between laboratory adherence to best
practices and patient effective dose was evaluated using
hierarchical linear regression models, accounting for
Table 1 Definition of the eight best practices
Item no. Best practice Definition Basis for recommendation
1 Avoid 201Tl stress No 201Tl studies performed in patients
≤70 years of age
SPECT imaging with 201Tl is associated with a
considerably higher radiation dose to patients
than 99mTc [18]. This practice excludes 201Tl
viability studies and stress-redistribution-
reinjection stress-and-viability studies
2 Avoid dual isotope imaging No dual isotope (rest 201Tl and stress
99mTc) studies performed in patients
≤70 years of age
Dual isotope imaging is associated with the
highest radiation dose of any protocol [18]
3 Avoid administration of too much 99mTc No study performed with 99mTc
activities >1,332 MBq (36 mCi),
and mean total effective dose <15 mSv
for all studies with two 99mTc injections
1,332 MBq is the highest recommended activity
in guidelines [21], and 15 mSv is a very high
radiation dose for a 99mTc study
4 Avoid administration of too much 201Tl For each study with 201Tl, less than
129.5 MBq administered during stress
The expert committee maintained that 129.5
MBq should be the upper threshold for 201Tl
activity
5 Perform stress-only imaging At least one stress-only study performed,
with rest imaging omitted, or only
PET-based stress tests performed
If stress images are completely normal,
subsequent rest imaging can be omitted
6 Use camera-based dose-reduction
strategies
At least one study performed using at
least one of the following: (1) attenuation
correction (CT or transmission source),
(2) imaging patients in multiple positions,
e.g. both supine and prone, (3)
high-technology software (e.g. resolution
recovery and noise reduction), and (4)
high-technology hardware (e.g. PET or
a solid-state CZT SPECT camera)
Each of these approaches reduces the
administered activity needed and facilitates
performance of stress-only imaging
7 Use weight-based dosing for 99mTc Positive correlation between patient weight
and administered activity (MBq) for
injections of 99mTc
Tailoring the administered activity to the patient
weight offers an opportunity to reduce
radiation dose
8 Avoid inappropriate dosing that can
lead to Bshine-through^ artefact
No SPECT studies performed with 99mTc
rest and stress injections on the same day,
in which the activity of the second injection
was less than three times that of the
first injection
Shine-through occurs in 1-day 99mTc studies
when residual radioactivity from the first
injection interferes with the images following
the second injection. To avoid shine-through,
guidelines recommend that the activity of the
second injection should be three to four times
higher than that of the first injection. A second
injection with an activity less than three times
the activity of the first injection can lead to
shine-through
A committee of international experts convened at the IAEA, including physicians andmedical physicists, developed these criteria to be applied to nuclear
cardiology laboratories. Each best practice, and thus also the quality score constituting the number of best practices adhered to, is defined for an
individual laboratory, not for an individual patient. Adapted from Einstein et al. [14]
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clustering at the laboratory and country levels. Regres-
sion coefficients corresponded to the expected change in
effective dose associated with adherence to a corre-
sponding best practice. Patient effective dose was used
as the dependent variable. The eight best practices were
included as dichotomous (laboratory adherence, yes or
no) independent variables and were treated as fixed fac-
tors. The intercept was defined as a random factor.
Analyses were performed with and without adjustment
for patient age, gender and weight. Correlations between
model variables were assessed using Pearson’s ϕ coeffi-
cient. Statistical tests were considered significant with a
two-tailed P value of <0.05. Analyses were performed
using Stata/SE 13.1 (StataCorp, College Station, TX).
Results
Global Europe versus the RoW
Data were collected on 2,381 patients in 102 laborato-
ries in 27 European countries with a mean of 23.3 ± 32.8
patients per laboratory (Table 2). Data from the RoW
were from 5,530 patients, 206 laboratories and 38 coun-
tries with a mean of 26.8 ± 31.0 patients per laboratory.
The list of the RoW countries is available elsewhere
[14]. A cardiac SPECT study was performed in 2,330
(97.9 %) of the European patients (RoW 5,110,
92.4 %), and a cardiac PET study in 51 (2.1 %) of
the European patients (RoW 420, 8.2 %).
The mean age of the European patients was 65.3 ±
11.1 years (RoW 63.7 ± 12.3 years, P< 0.001), and 40 %
were women (RoW 41.7 %, P= 0.13). The mean effec-
tive dose from SPECT was 8.0 ± 3.4 mSv (RoW 11.4 ±
4.3 mSv, P< 0.001) and from PET was 2.6 ± 1.5 mSv
(RoW 3.8 ± 2.5 mSv, P< 0.001). An effective dose of
>9 mSv was received by 961 (41.2 %) of the European
SPECT patients (RoW 3,874, 75.8 %, P< 0.001) and by
none of all PET patients. Stress-only SPECT protocols
were more frequent in Europe than in the RoW (19.7 %
versus 10.6 %, P< 0.001). Demographics and effective
doses are shown in Table 3.
Regional variation in Europe
European regions differed with respect to age and gen-
der. In laboratories in the West region, patients were
about 3 years older than in laboratories in the East
region. The proportion of women undergoing testing
varied from 35.0 % in the South region to 50.2 % in
the East region. The mean numbers of patients in the
observation week ranged from 17.4 to 34.5 per labora-
tory and did not differ significantly among the regions.
Both mean and median effective doses from SPECT and
from PET differed among the regions (P< 0.001 and P=
0.002, respectively). The effective dose from SPECT
was lowest in the North region. The effective doses in
the other regions were higher and similar to each other
(P= 0.099; Table 3). Correspondingly, the proportion of
studies with effective doses >9 mSv was higher in these
regions (range 41.0 % to 53.8 %) and lowest in the
North region (19.4 %, P< 0.001).
SPECT protocols
Table 4 shows the numbers of SPECTstress-first and rest-first
protocols. In Europe, significantly more stress-only protocols
were performed than in the RoW (19.8 % vs. 8.2 %,
Table 2 Participating European countries and number of laboratories according to the UN geoscheme
East North South West
Country No. of
laboratories
Country No. of
laboratories
Country No. of
laboratories
Country No. of
laboratories
Czech Republic 3 Denmark 1 Bosnia and Herzegovina 1 Austria 5
Hungary 4 Estonia 1 Croatia 2 Belgium 2
Poland 6 Finland 1 Italy 25 France 1
Romania 1 Latvia 2 FYROMa 2 Germany 3
Slovakia 1 Lithuania 1 Portugal 4 Luxembourg 1
Sweden 10 Serbia and Montenegro 2 Netherlands 1
United Kingdom 15 Slovenia 2 Switzerland 2
Spain 3
Total 15 31 41 15
a Former Yugoslav Republic of Macedonia
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P<0.0001) although there was large variation among Europe-
an centres (range 8.6 % to 33.4 %, P<0.001). The South
region had the lowest use of stress-only studies at 8.6 % with
more common and similar use in the other regions (24.0 % to
33.4 %).
Evaluation of quality scores
Quality scores are summarized in Tables 5 and 6. The
mean European quality score was 6.2 ± 1.2, which was
higher than that for the RoW (5.0 ± 1.1, P<0.001). More
European laboratories (70.6 %) adhered to six or more
best practices than in the RoW (34.0 %, P< 0.001). Ad-
herence to best practices did not vary among the Euro-
pean regions (range of mean quality score 6.0 to 6.4,
P= 0.73).
Radiation dose and adherence to best practices
Imaging in a laboratory that adhered to each of the best
practices was associated with a significantly lower ef-
fective dose with the exceptions of using weight-based
dosing of 99mTc (observed dose reduction not statistical-
ly significant), and avoiding inappropriate dosing that
could lead to shine-through. This relationship was main-
tained after adjusting for patient age, gender and weight.
Avoiding dual isotope use in patients <70 years of age
was associated with the largest reduction in effective
dose (9.51 mSv). The results of the hierarchical regres-
sion model adjusted for age, gender and weight are
shown in Table 7. Pair-wise correlations between quality
items were low. Pearson’s |ϕ| coefficient was less than
0.1 for most correlations, with modest correlations
Table 4 SPECT protocols in Europe and the rest-of-the-world (RoW)
East North South West Europe RoW
No. of patients with stress study first 144 440 812 401 1,797 1,674
No. of patients with rest study first, then stress study 97 36 134 66 333 2,911
Total no. of patients with stress studies 241 476 946 467 2,130 4,585
No. of patients excluded because of
undesirability of stress-only protocola
20 107 73 51 251 945
No (%) of patients with stress-only protocolb 70 (29.0 %) 159 (33.4 %) 81 (8.6 %) 112 (24.0) 422 (19.8 %) 378 (8.2 %)
a Stress-only imaging would be clinically undesirable in some patients (e.g. viability study, rest-only study); therefore study was excluded from analysis
of rate of stress-only studies
bP< 0.001 within Europe, P< 0.0001 Europe vs. RoW
Table 5 European quality scores
versus the rest-of-the-world
(RoW)
Europe Europe vs. RoW
East North South West P value Europe RoW P value
No. of laboratories 15 31 41 15 102 206
Scorea
1 0 0 0 0 n/a 0 0 n/a
2 0 0 0 0 n/a 0 2 n/a
3 0 0 0 0 n/a 0 15 n/a
4 1 4 2 3 0.007 10 46 0.007
5 3 5 10 2 0.004 20 73 0.004
6 6 6 11 5 0.89 28 54 0.817
7 4 7 14 2 <0.001 27 11 <0.001
8 1 9 4 3 <0.001 17 5 <0.001
≥6 11 22 29 10 0.99 72 70 <0.001
Mean ± SD 6.1 ± 1.0 6.4 ± 1.4 6.2 ± 1.1 6.0 ± 1.4 0.73 6.2 ± 1.2 5.0 ± 1.1 <0.001
Median 6 7 6 6 0.71 6 5 <0.001
Interquartile
range
5 – 7 5 – 8 5 – 7 5 – 7 5 – 7 4 – 6
aNumber of best practices out of eight adhered to by a laboratory
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observed between sex and weight (0.3), and use of the
best practices avoiding shine-through and stress-only
imaging (0.4).
Discussion
With the growing incidence of cardiovascular disease [22],
increasing use of nuclear cardiology is having an impact on
patient exposure to radiation. This paper presents the data of
the European subanalysis of the first worldwide study
(INCAPS) on nuclear cardiology imaging protocols, associat-
ed effective doses and quality scores focusing on radiation
exposure. Within the European Union, mandatory Council
directives for medical exposure have been established
since 1997 and implemented in the national laws of
member states. The earlier directive 97/43/Euratom from
June 1997 was replaced in December 2013 by the new
Council directive 2013/59/Euratom which further delin-
eates radiation protection standards for the European
Union. Member states are committed to promoting the
establishment and use of diagnostic reference levels
(DRL) for radiodiagnostic examinations that creates a
culture of radiation protection [23–25].
Effective doses
The effective doses in Europe (mean 8.0 mSv; median
8.1 mSv, IQR 5.4 – 10.2 mSv) were lower than in the RoW,
which could partly be because of the European regulations.
Guidelines recommend that the median effective dose should
be ≤9mSv, and this was the case for European laboratories but
Table 6 European best practices by region versus the rest-of-the-world (RoW)
Europe Europe vs. RoW
East North South West P value Europe RoW P value
No. of laboratories 15 31 41 15 102 206
Best practice
Avoid 201Tl stress 15 (100 %) 30 (97 %) 40 (98 %) 12 (80 %) 0.078 97 (95 %) 185 (90 %) 0.13
Avoid dual isotope imaging 14 (93 %) 31 (100 %) 41 (100 %) 15 (100 %) 0.294 101 (99 %) 197 (96 %) 0.17
Avoid administration of too much 99mTc 15 (100 %) 30 (97 %) 41 (100 %) 15 (100 %) 0.598 101 (99 %) 162 (79 %) <0.001
Avoid administration of too much 201Tl 15 (100 %) 31 (100 %) 41 (100 %) 15 (100 %) n/a 102 (100 %) 204 (99 %) 1
Perform stress-only imaging 4 (27 %) 17 (55 %) 18 (44 %) 8 (53 %) 0.308 47 (46 %) 46 (22 %) <0.001
Use camera-based dose-reduction strategies 11 (73 %) 22 (71 %) 26 (63 %) 12 (80 %) 0.677 71 (70 %) 135 (66 %) 0.48
Use weight-based dosing for 99mTc 5 (33 %) 17 (55 %) 21 (51 %) 5 (33 %) 0.365 48 (47 %) 40 (19 %) <0.001
Avoid inappropriate dosing that can lead
to Bshine-through^ artefact
12 (80 %) 20 (65 %) 26 (63 %) 8 (53 %) 0.514 66 (65 %) 70 (34 %) <0.001
Table 7 Relationships between
laboratory best practices and
predicted patient effective dose
from the final hierarchical
regression model
Best practice Reduction in predicted effective dose (mSv) P value
Mean 95 % confidence
interval
Standard
error
Avoid 201Tl stress 4.55 2.34 – 6.75 1.13 <0.001
Avoid dual isotope imaging 9.51 4.89 – 14.1 2.36 <0.001
Avoid administration of too much 99mTc 8.28 2.89 – 13.7 2.75 0.003
Avoid administration of too much 201Tl Omitted because all laboratories followed this best practice
Perform stress-only imaging 2.20 1.22 – 3.18 0.50 <0.001
Use camera-based dose-reduction strategies 1.13 0.15 – 2.11 0.50 0.023
Use weight-based dosing for 99mTc 0.45 −0.51 – 1.42 0.49 0.356
Avoid shine-through −1.04 −2.05 – −0.27 0.52 0.044
Age (years) −0.003 −0.01 – 0.005 0.004 0.508
Female gender 0.44 0.25 – 0.62 0.09 <0.001
Weight (kg) −0.04 −0.05 – −0.038 0.003 <0.001
Intercept (predicted effective dose) 28.7 21.1 – 36.2 3.84 <0.001
Regression model accounts for clustering within laboratory and country
724 Eur J Nucl Med Mol Imaging (2016) 43:718–728
there was variation among regions with the North having the
lowest effective dose and only 19 % of patients receiving an
effective dose above 9 mSv. Interestingly, effective doses in
all the other regions were found to be very similar. The vari-
ability in effective doses in Europe can partly be explained by
the different patterns in the use of PETand SPECT. Because of
the short half-life of PET radiopharmaceuticals, the PET ef-
fective doses were lower than those used in SPECT, both in
Europe and in the RoW. Given that PET is more sensitive for
the detection of coronary artery disease [26], our data support
efforts to increase access to and the use of cardiac PET. Patient
effective doses must also be considered in the light of risk
from cardiac disease, appropriateness of imaging and patient
age. A recent analysis addressing these issues demonstrated
that the long-term risk of patient exposure to radiation from
noninvasive cardiac imaging is low and that the appropriate
use of imaging the life-time risk of imaging procedures for
fatal events is small compared with the risk of fatal cardiac
events by coronary artery disease [27].
Evaluation of quality scores and best practices
The worldwide INCAPS analysis found lower effective doses
in patients who underwent cardiac SPECT and PET proce-
dures in laboratories with better adherence to best practice
[14]. Accordingly, adherence to radiation dose-related best
practices was significantly better in Europe (quality score
6.2) than in the RoW (quality score 5.0). Although not statis-
tically significant, quality parameters in the North European
region were better than in the other regions which may explain
the lower effective dose in Europe (Table 5). At least 17 % of
all European laboratories followed all best practices (RoW
2 %), so 83 % have the potential, and according to the
ALARA principle also the responsibility, to further increase
their use of best practices.
As observed in multivariable modelling in the world-
wide INCAPS study [14], in this European analysis the
greatest benefit in terms of reducing dose was achieved
through avoiding dual isotope imaging, followed by
avoiding administration of too much 99mTc, avoiding
201Tl stress testing, using stress-only imaging, and using
camera-based does-reduction strategies. Stress-only imag-
ing has been shown to reduce exposure of the individual
patient to radiation by about 75 % if a 1-day stress–rest
protocol was initially planned, or by about 50 % if a 2-
day stress–rest protocol was planned. It entails performing
the stress study first and then omitting the rest study in
patients with unequivocally normal stress images. The pro-
tocol has been validated in large clinical studies and has
no diagnostic disadvantages over routine acquisition of
both stress and rest images [28]. Of the individual best
practices, stress-only imaging was among the practices
with low adherence in Europe and in the RoW. The South
region of Europe had the lowest proportion of stress-only
studies (8.6 %). In the North region the proportion was
30 % (Table 4). The 19 % of rest-first studies in Europe
shows that there is the potential to increase the number of
stress-only studies.
Similar reasoning applies to weight-based dosing, which
was also one of the quality practices with low adherence. A
recent study in three Italian centres has shown the effective-
ness of this practice and indicates that factors to reduce effec-
tive doses have been recognized and are being implemented
[11].
German surveys covering the years 2005 to 2012 have
shown a decrease in effective dose from nuclear cardiology
procedures over time and also that implementation of best
practices takes time [13]. The changes in effective dose in
Germany have been largely a result of the reduced use of
201Tl, which is now of only minor importance in Europe. As
Table 6 shows, there are only a few laboratories that still use
201Tl or dual isotope imaging.
Limitations
This study had several limitations. First, the number of
responding European laboratories was modest, contributions
from some European countries were missing, and for some
regions the distribution of laboratories may have been imper-
fectly reflected by the distribution of participating laborato-
ries; e.g. in the South region, Italy is either over-represented or
has many more laboratories than other countries. The true
number of laboratories practicing nuclear cardiology in Eu-
rope is unknown and it is unclear if the data are representative
of overall European practice since responders may be a moti-
vated subset of laboratories with good practice. Nevertheless,
a comparison with current national survey data reveals that the
data are plausibly representative [13, 29]. One implication of
the uncertain response rate is the need to establish a database
of European laboratories performing nuclear medicine proce-
dures. Indeed, such a project is currently under consideration
under EANM auspices. Second, the study involved only a
single week, and thus, is potentially not representative of each
laboratory’s practice.
Third, one can imagine rare individual clinical sce-
narios where non-adherence to some of the best prac-
tices identified by our expert panel is justified. Howev-
er, we believe that careful attention to the specified best
practices by a laboratory is indicative of reduced expo-
sure to radiation of patients in the laboratory’s care,
notwithstanding such exceptions. Nevertheless, as the
quality score was derived from the best practices with-
out weighting, caution should be used in interpreting the
impact of the score on predicted effective dose. That is,
in the case of a quality score <8 an identical score may
have different implications on effective dose depending
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on the particular best practices followed. Fourth, the
study focused on optimizing radiation dose and not on
the justification for or appropriateness of nuclear cardiac
testing. Radiation exposure can also be minimized by
avoiding inappropriate examinations [18]. Finally, as
INCAPS did not assess image quality, the relationships
between radiation best practices and image quality could
not be evaluated.
Conclusion
While nuclear cardiology procedures have numerous benefits,
they expose patients to ionizing radiation. The mean effective
dose in a patient undergoing cardiac SPECTor PET in Europe
is lower, and the quality score higher, than in the RoW. One
reason for the European position may be the safety culture
fostered by the Euratom directives for medical exposure im-
plemented in the national laws of member states, the first in
1997 and the second in 2013. The use of stress-only protocols
and weight-adjusted dosing of radiopharmaceuticals are po-
tential targets for optimizing effective doses in patients under-
going nuclear cardiology imaging in Europe.
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